Clinical Trials Directory

Trials / Completed

CompletedNCT02689999

The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Neutec Ar-Ge San ve Tic A.Ş · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

It is planned to investigate the effect of dexrabeprazole on gastric acid primarily, and then gastroesophageal reflux disease (GERD) symptoms, intraesophageal acidity (reflux) and impedance kinetics.

Detailed description

The participants will be on one week medication after two-weeks observation period. Intragastric and intraesophageal multichannel intraluminal impedance-pH (pH-MII) monitoring will be performed before and after medication. The pre- and post-treatment data will be compared. The safety tests will be performed during study in terms of possible side effects.

Conditions

Interventions

TypeNameDescription
DRUGDexrabeprazole 10 mg Enteric-Coated Tablets

Timeline

Start date
2016-02-01
Primary completion
2017-05-01
Completion
2017-08-01
First posted
2016-02-24
Last updated
2017-08-24

Locations

3 sites across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT02689999. Inclusion in this directory is not an endorsement.

The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity (NCT02689999) · Clinical Trials Directory